Medpace vs Mettler Toledo
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Medpace and Mettler Toledo side by side, using each one’s latest annual report. Here is what stands out:
- Mettler Toledo is the larger business, with $4.0B of revenue in fiscal 2025 against $2.5B for Medpace, about 1.6 times as much.
- Medpace grew revenue faster (20.0%, against 4.0%).
- Medpace turned more of its sales into free cash flow (27.0% FCF margin, against 21.1%).
- Investors pay more for each dollar of Mettler Toledo’s earnings: a P/E of 37.6x against 37.6x for Medpace.
Who comes out ahead
Of the 7 measures where higher (or lower) is clearly better, how many each company leads.
Medpace
MEDP
5/7
Revenue growth5-year growthFCF marginNet debt / EBITDAShare count change
Mettler Toledo
MTD
2/7
Net marginPiotroski F-score
Side by side
Best in the row
| Latest fiscal year | MEDP FY25 | MTD FY25 |
|---|---|---|
| Size | ||
| Market cap | $19.2B | $33.7B |
| Revenue | $2.5B | $4.0B |
| Free cash flow | $682M | $849M |
| Net income | $451M | $869M |
| Growth | ||
| Revenue growth | 20.0% | 4.0% |
| 5-year growth | 22.3% | 5.5% |
| Share count change | −7.8% | −3.0% |
| Profitability | ||
| Gross margin | — | 59.4% |
| Operating margin | 21.1% | — |
| Net margin | 17.8% | 21.6% |
| FCF margin | 27.0% | 21.1% |
| Return on capital | — | 50.5% |
| Return on equity | 70.2% | — |
| Balance sheet | ||
| Net debt | −$497M | $2.0B |
| Net debt / EBITDA | −0.9x | 1.7x |
| Dividends and buybacks | $917M | $800M |
| Valuation & quality | ||
| P/E | 37.6x | 37.6x |
| Piotroski F-score | 4 | 7 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.